Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Sanofi Pasteur's quadrivalent influenza vaccine now available for the 2017-2018 influenza season

Sanofi Pasteur
Posted on: 12 Sep 17

Sanofi Pasteur, the vaccines division of Sanofi, announced today that, for the first time, it is making available its quadrivalent influenza vaccine in the UK. The United Kingdom (UK) is the first European country to market Sanofi Pasteur’s quadrivalent influenza vaccine.

“Flu is an unpredictable virus which can lead to serious complications, hospitalisation, and in some cases even fatalities, especially for those in at risk patient groups and in particular those above 65 years as well as those with chronic diseases like asthma, heart disease and diabetes,” said Dr Ian Gray, Medical Head, Sanofi Pasteur UK & Ireland. “The UK authorities are leading the way in Europe by encouraging those in at risk groups to get vaccinated against flu. Sanofi Pasteur fully supports such immunisation policies by developing innovative vaccines that fit with the influenza epidemiology, providing the option for broad protection for those aged 3 years and older.”

Currently, the majority of seasonal influenza vaccines are trivalent, meaning that they protect against three strains of influenza virus: two A strains and one single B strain. However, over the recent flu seasons, co-circulation of two B strains has been consistently observed. For example, in 2015 92% of documented B strain-related cases of influenza reported in Europe were caused by a B strain which was not included in the available trivalent vaccines during that season[1]. The quadrivalent influenza vaccines include both B strains. By adding protection against the additional B strain, these innovative vaccines help address the unpredictable nature of B strain circulation, thus broadening protection against influenza.

Sanofi Pasteur’s quadrivalent influenza vaccine obtained its marketing authorisation in the European Union in June 2016 and in the UK later that year. It is now available in the UK in addition to the current influenza vaccines.

Hugo Fry, General Manager of Sanofi Pasteur UK & Ireland explains, “Sanofi Pasteur, the world’s largest manufacturer of influenza vaccines, remains at the forefront of innovation to fight the known burden of influenza. Over the next few years our vaccine portfolio will evolve further and Sanofi Pasteur will continue to support public health needs”. 

Editor's Details

Sanofi Pasteur
Red Consultancy
2070256564
elspeth.houlding@redconsultancy.com

Last updated on: 12/09/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.